Published in Pharmacol Rev on June 01, 2003
Inflammation and insulin resistance. FEBS Lett (2007) 3.34
The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol (2009) 2.87
Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol (2010) 2.44
Signalling pathways in alcohol-induced liver inflammation. J Hepatol (2009) 2.29
IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ Res (2008) 2.01
Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood (2014) 1.95
Interleukin-10 suppression of myeloid cell activation--a continuing puzzle. Immunology (2004) 1.95
Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol Rev (2008) 1.88
Protecting against vascular disease in brain. Am J Physiol Heart Circ Physiol (2011) 1.66
IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther (2013) 1.66
IL-10 inhibits miR-155 induction by toll-like receptors. J Biol Chem (2010) 1.65
Posttranscriptional regulation of interleukin-10 expression by hsa-miR-106a. Proc Natl Acad Sci U S A (2009) 1.64
Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency. J Clin Lipidol (2014) 1.58
Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation. Proc Natl Acad Sci U S A (2010) 1.50
Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol (2004) 1.48
Regulatory B cells suppress imiquimod-induced, psoriasis-like skin inflammation. J Leukoc Biol (2013) 1.48
Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest (2005) 1.42
Endogenous interleukin-10 inhibits angiotensin II-induced vascular dysfunction. Hypertension (2009) 1.38
Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function. J Clin Invest (2009) 1.35
IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol (2004) 1.28
The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol (2012) 1.23
Scorpion venom and the inflammatory response. Mediators Inflamm (2010) 1.20
Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2012) 1.19
Current status of interleukin-10 and regulatory T-cells in cancer. Curr Opin Oncol (2013) 1.17
Targeting the "cytokine storm" for therapeutic benefit. Clin Vaccine Immunol (2013) 1.17
Peritoneal cavity regulatory B cells (B10 cells) modulate IFN-γ+CD4+ T cell numbers during colitis development in mice. J Immunol (2013) 1.12
A helminth immunomodulator exploits host signaling events to regulate cytokine production in macrophages. PLoS Pathog (2011) 1.10
Intraocular and serum cytokine profiles in patients with intermediate uveitis. Mol Vis (2011) 1.10
Growth of Yersinia pseudotuberculosis in mice occurs independently of Toll-like receptor 2 expression and induction of interleukin-10. Infect Immun (2007) 1.10
MR T1ρ as an imaging biomarker for monitoring liver injury progression and regression: an experimental study in rats with carbon tetrachloride intoxication. Eur Radiol (2012) 1.05
Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells. Immunology (2008) 1.03
The structural network of Interleukin-10 and its implications in inflammation and cancer. BMC Genomics (2014) 1.02
Why interleukin-10 supplementation does not work in Crohn's disease patients. World J Gastroenterol (2013) 1.02
Overexpression and interactions of interleukin-10, transforming growth factor beta, and vascular endothelial growth factor in esophageal squamous cell carcinoma. World J Surg (2009) 0.99
IL-10 within the CNS is necessary for CD4+ T cells to mediate neuroprotection. Brain Behav Immun (2010) 0.97
Hydrodynamic delivery of mIL10 gene protects mice from high-fat diet-induced obesity and glucose intolerance. Mol Ther (2013) 0.97
Expression and regulation of CCL18 in synovial fluid neutrophils of patients with rheumatoid arthritis. Arthritis Res Ther (2007) 0.97
Pathologic patterns of interleukin 10 expression--a review. Biochem Med (Zagreb) (2015) 0.97
Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease. Hum Mol Genet (2012) 0.96
Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract (2012) 0.95
Immunosuppressive/anti-inflammatory cytokines directly and indirectly inhibit endothelial dysfunction--a novel mechanism for maintaining vascular function. J Hematol Oncol (2014) 0.95
Regulation of production of mucosal antibody to pneumococcal protein antigens by T-cell-derived gamma interferon and interleukin-10 in children. Infect Immun (2006) 0.94
Schistosome infection intensity is inversely related to auto-reactive antibody levels. PLoS One (2011) 0.94
Cell encapsulating biomaterial regulates mesenchymal stromal/stem cell differentiation and macrophage immunophenotype. Stem Cells Transl Med (2012) 0.92
Cytokine control of inflammation and repair in the pathology of multiple sclerosis. Yale J Biol Med (2012) 0.92
Aspergillus-associated airway disease, inflammation, and the innate immune response. Biomed Res Int (2013) 0.91
Rapamycin combined with anti-CD45RB mAb and IL-10 or with G-CSF induces tolerance in a stringent mouse model of islet transplantation. PLoS One (2011) 0.91
Does immune activation continue during an attack-free period in familial Mediterranean fever? Clin Exp Immunol (2004) 0.91
A novel mechanism of B cell-mediated immune suppression through CD73 expression and adenosine production. J Immunol (2014) 0.90
The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. Biomaterials (2014) 0.90
The role of CD4CD25 T cells in autoantibody production in murine lupus. Clin Exp Immunol (2006) 0.89
Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model. J Exp Clin Cancer Res (2008) 0.89
Staphylococcus aureus induces microglial inflammation via a glycogen synthase kinase 3beta-regulated pathway. Infect Immun (2009) 0.89
IL-10 induction by Bordetella parapertussis limits a protective IFN-gamma response. J Immunol (2009) 0.89
Expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in hepatic stellate cells during rat hepatic fibrosis and its intervention by IL-10. World J Gastroenterol (2005) 0.88
Modulation of cytokine expression in human myeloid dendritic cells by environmental endocrine-disrupting chemicals involves epigenetic regulation. Environ Health Perspect (2010) 0.88
Therapeutic effect of interleukin-10 on CCl4-induced hepatic fibrosis in rats. World J Gastroenterol (2006) 0.88
Macrophage immunoregulatory pathways in tuberculosis. Semin Immunol (2014) 0.88
Efficacy of intracolonic administration of low-molecular-weight heparin CB-01-05, compared to other low-molecular-weight heparins and unfractionated heparin, in experimentally induced colitis in rat. Dig Dis Sci (2008) 0.87
Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features. Clin Exp Immunol (2015) 0.86
Interferon beta overexpression attenuates adipose tissue inflammation and high-fat diet-induced obesity and maintains glucose homeostasis. Gene Ther (2016) 0.86
Interaction between oral lichen planus and chronic periodontitis with Th17-associated cytokines in serum. Inflammation (2013) 0.86
Eosinophil activity in Schistosoma mansoni infections in vivo and in vitro in relation to plasma cytokine profile pre- and posttreatment with praziquantel. Clin Vaccine Immunol (2006) 0.86
Immune system inflammation in cocaine dependent individuals: implications for medications development. Hum Psychopharmacol (2012) 0.86
Therapeutical measures to control airway tolerance in asthma and lung cancer. Front Immunol (2012) 0.86
Gene expression profile of endotoxin-stimulated leukocytes of the term new born: control of cytokine gene expression by interleukin-10. PLoS One (2013) 0.86
The -1082A>G polymorphism in promoter region of interleukin-10 and risk of digestive cancer: a meta-analysis. Sci Rep (2014) 0.86
Functional recovery and facial motoneuron survival are influenced by immunodeficiency in crush-axotomized mice. Exp Neurol (2009) 0.86
Effects of overexpression of IL-10, IL-12, TGF-beta and IL-4 on allergen induced change in bronchial responsiveness. Respir Res (2006) 0.86
Virally expressed interleukin-10 ameliorates acute encephalomyelitis and chronic demyelination in coronavirus-infected mice. J Virol (2011) 0.86
Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis. PLoS One (2012) 0.86
Effect of scaling and root planing on serum interleukin-10 levels and glycemic control in chronic periodontitis and type 2 diabetes mellitus. J Indian Soc Periodontol (2015) 0.86
Viral and murine interleukin-10 are correctly processed and retain their biological activity when produced in tobacco. BMC Biotechnol (2009) 0.86
CD4+CD25hiCD127low regulatory T cells are increased in oral squamous cell carcinoma patients. PLoS One (2014) 0.86
Inhalative IL-10 attenuates pulmonary inflammation following hemorrhagic shock without major alterations of the systemic inflammatory response. Mediators Inflamm (2011) 0.86
Altered CD46-mediated T cell co-stimulation in haemodialysis patients. Clin Exp Immunol (2005) 0.85
Suppressor of cytokine signalling-3 at pathological levels does not regulate lipopolysaccharide or interleukin-10 control of tumour necrosis factor-alpha production by human monocytes. Immunology (2006) 0.85
Enforced expression of roquin protein in T cells exacerbates the incidence and severity of experimental arthritis. J Biol Chem (2012) 0.85
The interleukin-10 promoter polymorphism rs1800872 (-592C>A), contributes to cancer susceptibility: meta-analysis of 16,785 cases and 19,713 controls. PLoS One (2013) 0.85
Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism--effects of medication. Behav Brain Funct (2010) 0.85
Interleukin-10 attenuates vascular responses to endothelin-1 via effects on ERK1/2-dependent pathway. Am J Physiol Heart Circ Physiol (2008) 0.84
An intracytoplasmic IL-10 receptor variant permits rapid reduction in STAT3 activation. Genes Immun (2011) 0.84
Characterization of Anti-HCV Antibodies in IL-10-Treated Patients. Viral Immunol (2010) 0.84
Pro-inflammatory and pro-oxidant status of pancreatic islet in vitro is controlled by TLR-4 and HO-1 pathways. PLoS One (2014) 0.84
Serum proinflammatory cytokines directing T helper 1 polarization in patients with familial Mediterranean fever. Rheumatol Int (2007) 0.84
IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma. Blood Cancer J (2015) 0.84
Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse. Arthritis Res Ther (2013) 0.84
Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases. ISRN Gastroenterol (2011) 0.83
Lactococcus lactis carrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis. BMC Biotechnol (2014) 0.83
Brief report: "allergic symptoms" in children with Autism Spectrum Disorders. More than meets the eye? J Autism Dev Disord (2011) 0.83
3D domain swapping causes extensive multimerisation of human interleukin-10 when expressed in planta. PLoS One (2012) 0.83
Inflammatory events during murine squamous cell carcinoma development. J Inflamm (Lond) (2012) 0.82
Transcriptional control of cytokine release from monocytes of the newborn: effects of endogenous and exogenous interleukin-10 versus dexamethasone. Neonatology (2009) 0.82
Immunological priming requires regulatory T cells and IL-10-producing macrophages to accelerate resolution from severe lung inflammation. J Immunol (2014) 0.82
Interleukin-10: a pleiotropic regulator in pregnancy. Am J Reprod Immunol (2014) 0.82
Loss of tissue expression of interleukin-10 promotes the disease progression of colorectal carcinoma. Surg Today (2009) 0.82
Interleukin-10: an anti-inflammatory marker to target atherosclerotic lesions via PEGylated liposomes. Mol Pharm (2012) 0.81
Pro- and anti-inflammatory cytokines release in mice injected with Crotalus durissus terrificus venom. Mediators Inflamm (2008) 0.81
Suppression of experimental autoimmune encephalomyelitis by interleukin-10 transduced neural stem/progenitor cells. J Neuroinflammation (2013) 0.81
CD19(+) B cells confer protection against experimental cerebral malaria in semi-immune rodent model. PLoS One (2013) 0.81
MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol (1999) 5.75
Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med (1997) 5.19
Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet (1999) 3.01
Country profile: Germany. Lancet (1996) 2.77
T-cell epitope mapping by flow cytometry. Nat Med (1998) 2.56
Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol (1999) 2.55
Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions. Clin Pharmacol Ther (1999) 2.33
Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med (1998) 2.30
Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol (2000) 2.29
Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury. J Clin Invest (1999) 2.29
Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation (2000) 2.18
Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med (1995) 2.03
Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun (2009) 1.81
Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int Immunol (1995) 1.81
Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial. Neuroscience (2008) 1.75
Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer and the follicular orifice. Skin Pharmacol Appl Skin Physiol (1999) 1.67
Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med (1991) 1.66
Systemic inflammation in patients with heart failure. Eur Heart J (1998) 1.64
Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet (1995) 1.63
Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol (1997) 1.63
Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells. Eur J Immunol (1999) 1.63
Distribution of human CMV-specific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoforms. Eur J Immunol (1999) 1.62
Detection of early micrometastases in subcutaneous fat of primary malignant melanoma patients by identification of tyrosinase-mRNA. Eur J Cancer (1996) 1.59
Organization of the monocyte/macrophage system of normal human skin. J Invest Dermatol (1990) 1.58
Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood (2000) 1.58
Analysis of V(H)-D-J(H) gene transcripts in B cells infiltrating the salivary glands and lymph node tissues of patients with Sjögren's syndrome. Arthritis Rheum (1999) 1.56
Cytomegalovirus reactivation and tumour necrosis factor. Lancet (1994) 1.55
Is there an interaction between interleukin-10 and interleukin-22? Genes Immun (2005) 1.54
Polyclonal expansion of T cells with the TCR V beta type of the tumour cell in lesions of cutaneous T-cell lymphoma: evidence for possible superantigen involvement. Br J Dermatol (2004) 1.53
Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood (1995) 1.52
New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis (2005) 1.47
Demonstration of frequent occurrence of clonal T cells in the peripheral blood but not in the skin of patients with small plaque parapsoriasis. Blood (1999) 1.47
Hypocomplementaemic urticarial vasculitis: successful treatment with cyclophosphamide-dexamethasone pulse therapy. Br J Dermatol (1998) 1.47
Immunomodulatory therapies in sepsis. Intensive Care Med (2000) 1.45
Identification of common dermatophytes (Trichophyton, Microsporum, Epidermophyton) using polymerase chain reactions. Br J Dermatol (1998) 1.44
T-cell receptor and immunoglobulin gene rearrangements in cutaneous T-cell-rich pseudolymphomas. J Invest Dermatol (1990) 1.43
A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol (2007) 1.42
IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest (1998) 1.40
Verrucosis of hands and feet in a patient with combined immune deficiency. J Am Acad Dermatol (1997) 1.39
Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNFalpha is mediated via induction of NF-kappaB. Virology (1995) 1.38
Hyperventilation induces release of cytokines from perfused mouse lung. Am J Respir Crit Care Med (1998) 1.36
Tumour necrosis factor alpha stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells. J Gen Virol (1993) 1.33
A novel link between stress and human cytomegalovirus (HCMV) infection: sympathetic hyperactivity stimulates HCMV activation. Virology (2000) 1.32
Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies. Intensive Care Med (2001) 1.32
Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol (2009) 1.28
Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol (2007) 1.28
Granulocyte-macrophage colony-stimulating factor and IFN-gamma restore the systemic TNF-alpha response to endotoxin in lipopolysaccharide-desensitized mice. J Immunol (1997) 1.26
Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol (2005) 1.25
A continuous T-cell line from a patient with Sézary syndrome. Arch Dermatol Res (1987) 1.23
Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol (2007) 1.21
Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. Biol Chem Hoppe Seyler (1996) 1.20
Sclerotherapy for treatment of hemangiomas. Dermatol Surg (2000) 1.19
Mechanisms of brain-mediated systemic anti-inflammatory syndrome causing immunodepression. J Mol Med (Berl) (1999) 1.18
Candida africana sp. nov., a new human pathogen or a variant of Candida albicans? Mycoses (2001) 1.14
A novel multispecific competitor fragment for quantitative PCR analysis of cytokine gene expression in rats. J Immunol Methods (1994) 1.14
Lipopolysaccharide-induced interleukin-10 in mice: role of endogenous tumor necrosis factor-alpha. Eur J Immunol (1995) 1.13
Hair follicles--an efficient storage and penetration pathway for topically applied substances. Summary of recent results obtained at the Center of Experimental and Applied Cutaneous Physiology, Charité -Universitätsmedizin Berlin, Germany. Skin Pharmacol Physiol (2008) 1.12
Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene (2006) 1.12
Sunscreen application at the beach. J Cosmet Dermatol (2004) 1.12
Oligonucleotide typing reveals association of type I psoriasis with the HLA-DRB1*0701/2, -DQA1*0201, -DQB1*0303 extended haplotype. J Invest Dermatol (1993) 1.12
CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol (2006) 1.10
Pneumoperitoneum with carbon dioxide stimulates growth of malignant colonic cells. Surgery (1997) 1.10
Influence of monomethylfumarate on monocytic cytokine formation--explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res (1997) 1.09
Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transpl Infect Dis (1999) 1.09
Peripheral blood T cell clonality in mycosis fungoides -an independent prognostic marker? J Invest Dermatol (2000) 1.08
Contact urticaria and dermatitis from self-adhesive pads. Contact Dermatitis (1985) 1.08
Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med (1997) 1.06
Tumor necrosis factor-induced apoptosis during the poisoning of mice with hepatotoxins. Gastroenterology (1997) 1.05
Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res (2000) 1.05
Differential regulation of monocytic tumor necrosis factor-alpha and interleukin-10 expression. Eur J Immunol (1996) 1.05
Human cytomegalovirus (HCMV) encephalitis in an immunocompetent young person and diagnostic reliability of HCMV DNA PCR using cerebrospinal fluid of nonimmunosuppressed patients. J Clin Microbiol (1998) 1.05
Case report. Osteomyelitis caused by high resistant Candida guilliermondii. Mycoses (1999) 1.04
Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein. Immunity (1998) 1.04
Adhesion molecule mapping in normal human skin. Arch Dermatol Res (1989) 1.04
Cytomegalovirus infection and common variable immunodeficiency. Lancet (1992) 1.04
Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells. Cytokine (2000) 1.04
The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol (2003) 1.04
Immunodepression following neurosurgical procedures. Crit Care Med (1995) 1.03
Distribution of bacteria in the epidermal layers and hair follicles of the human skin. Skin Pharmacol Physiol (2011) 1.03
Quantitative PCR analysis of cytokine transcription patterns in peripheral mononuclear cells after anti-CD3 rejection therapy using two novel multispecific competitor fragments. Transplantation (1994) 1.02
A family study of atopic dermatitis. Clinical and genetic characteristics of 188 patients and 2,151 family members. Arch Dermatol Res (1990) 1.01
Online lectures for students in dermatology: a replacement for traditional teaching or a valuable addition? J Eur Acad Dermatol Venereol (2009) 1.01
Very low monocytic HLA-DR expression indicates high risk of infection--immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. Eur J Emerg Med (1995) 1.00
Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol (1996) 1.00
The enigma of CD57+CD28- T cell expansion--anergy or activation? Clin Exp Immunol (1996) 0.99
Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br J Dermatol (2003) 0.99
Genomic organization of the gene coding for TIRC7, a novel membrane protein essential for T cell activation. Genomics (1999) 0.99
Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome. Leukemia (2011) 0.99
Reflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses. Dermatology (2009) 0.99
Mycetoma due to Exophiala jeanselmei and Mycobacterium chelonae in a 73-year-old man with idiopathic CD4+ T lymphocytopenia. Mycoses (1996) 0.99
CD4+CD7- leukemic T cells from patients with Sézary syndrome are protected from galectin-1-triggered T cell death. Leukemia (2002) 0.98